Amgen, Cytokinetics and Servier announce continuation of GALACTIC-HF following analysis
Amgen, Cytokinetics and Servier announced the DMC for GALACTIC-HF completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct. March 20, 2019